🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
18,156
Companies
1,062
Drugs tracked
3,385

Quick answer

NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

30 results for “Pharm Research Associates (UK) Limited” Clear

  1. Debio 0123 in combination with carboplatin and etoposide in adult participants with small cell lung cancer that recurred or progressed after platinum-based therapy.

    Pharm Research Associates (UK) Limited

    Small cell lung cancer

    phase 1 other active

    1 trial
  2. Debio 0123, Debio 0123, Debio 0123, Debio 2513, Debio 0123, Debio 2513, Debio 0123, Debio 0123

    Pharm Research Associates (UK) Limited

    Advanced solid tumors with CCNE1 amplification or deleterious mutations in FBXW7 or other proprietary gene

    phase 1 small molecule active

    1 trial
  3. Randomized, open-label, single-dose, two-period, cross-over, bioequivalence study comparing Linagliptin 5 mg film-coated tablets (Vipharm S.A.) to Trajenta® 5 mg film-coated tablets (Boehringer Ingelheim) in healthy volunteers under fasting conditions.

    Pharm Research Associates (UK) Limited

    Bioequivalence study in healthy volunteers under fasting conditions

    phase 1 other active

    1 trial
  4. Safety, Tolerability and Pharmacokinetic Profile of TPT0301 in Healthy Volunteers

    Pharm Research Associates (UK) Limited

    adjunctive neuropathic pain

    phase 1 other active

    1 trial
  5. Vehicle to Methylprednisolone Aceponate Ointment, Methylprednisolone Aceponate Ointment, Advantan® 0,1% Salbe

    Pharm Research Associates (UK) Limited

    Mild to moderate atopic dermatitis

    phase 1 small molecule active

    1 trial
  6. Placebo suspension is identical to Symbioflor®2 liquid formulation in appearance, weight and composition, with the exception that the active ingredient will be omitted. Placebo constitutes are sodium chloride, magnesium sulphate 7H2O, potassium chloride, calcium chloride 2H2O, magnesium chloride 6H2O, and purified water, Symbioflor 2 Tropfen zum Einnehmen, Suspension

    Pharm Research Associates (UK) Limited

    Irritable Bowel Syndrome

    approved small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources